News
Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the Bcl-2 inhibitor venetoclax. Its significant advantage is the potential to achieve deep remission, including undetectable minimal residual disease (MRD). Unlike other targeted drugs, it can be administered for a limited period of time. The following text presents current data from clinical trials and information on the strategy of selecting and sequencing targeted CLL treatment.
Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients…
Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a…
Probiotics as a Means to Reduce the Incidence of Streptococcus Mutans
Data from a prospective study examining the effects of probiotics on the oral microbiome show the…
Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data…
Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes…
Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy
Despite advances in the therapy of bronchial asthma, a portion of patients still do not achieve the…
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group…
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the…
Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta…